Dupilumab

UNC Health Provider Ushers in First FDA-Approved Medication for Eosinophilic Esophagitis

Retrieved on: 
Thursday, December 22, 2022
Research, General Health, Pharmaceutical, Other Education, Continuing, University, Education, Clinical Trials, Science, FDA, Other Science, Health, The New England Journal of Medicine, Eosinophilic esophagitis, Esophagus, Immunology, Clinical trial, Plasma protein binding, A. Lee Dellon, Communication, Stomach, American College, UNC School of Medicine, Polyp (medicine), Dysphagia, Skin, Dupilumab, Enzyme inhibitor, Inflammation, Multimedia, Food, American College of Allergy, Asthma and Immunology, Irritation, Eosinophil, Patient, Asthma, Infection, Physician, Parasitism, Swelling, FDA, EOE, Regeneron Pharmaceuticals, Sinusitis, Degenerative disease, Colon, Endoscopy, Diagnosis, MPH, Dermatitis, Annals of Allergy, Asthma & Immunology, Biopsy, Electric battery, Pharmaceutical industry, Medical imaging, MD, Allergy, Medicine

Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.

Key Points: 
  • Eosinophilic esophagitis (EoE) is an allergic condition of the esophagus that is on the rise throughout the United States.
  • View the full release here: https://www.businesswire.com/news/home/20221222005534/en/
    Evan Dellon, MD, MPH, professor of medicine at the UNC School of Medicine and director of the Center for Esophageal Diseases and Swallowing.
  • There is one approved treatment for EoE in several other countries, but it is not available for use in the United States.
  • Dellon believes that initially most doctors will prescribe the therapy for their more severe patients who weren’t responding to prior therapies.

With Approximately 45% of Eosinophilic Esophagitis Patients Going Undiagnosed, the Growth Opportunity for Sanofi/Regeneron's Dupixent and Future Advanced Therapies Could Be Significant, According to Spherix

Retrieved on: 
Monday, December 5, 2022
Physician, Nephrology, Diagnosis, Patient, Allergist, Gastroenterology, Research, Eosinophilic esophagitis, AstraZeneca, EOE, Disease, FDA, Neurology, BMS, Ophthalmology, Rheumatology, Dysphagia, Dermatology, Eosinophil, Pharmaceutical industry, Medicine, Dupilumab

EXTON, Pa., Dec. 5, 2022 /PRNewswire/ -- Sanofi/Regeneron significantly changed the EoE treatment landscape last May when the FDA approved Dupixent (dupilumab) to treat adult and pediatric patients suffering from eosinophilic esophagitis (EoE). Spherix Global Insights' recent research via their Market Dynamix™ EoE service suggests dupilumab's first mover advantage may yield greater dividends when taking into account physician experience managing the disease.

Key Points: 
  • While both gastroenterologists and allergists express satisfaction with Dupixent, their interest in more advanced options remains high, primarily driven by the common failures in first- and second-line treatment.
  • When asked about the appropriate placement of biologics in the treatment pathway, allergists feel strongly about earlier introduction versus their gastro counterparts.
  • Data suggests that both specialties pursue the same primary clinical outcome of improving patients' ability to swallow (reduced dysphagia) using different means.
  • Surmounting access and affordability barriers for advanced medication is cited by both specialties as key to helping patients achieve the best clinical outcome.

Atopic Dermatitis Treatment Global Market Report 2022: Increasing Adoption of Biological Therapies Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Vitamin D, Face, Groin, Skin, HPA, Food allergy, Dupilumab, Dermatitis, Atopic dermatitis, Asthma, Research, Cancer, Clinical trial, Growth, FDA, Calcineurin, Allergic rhinitis, II, Patient, Neck, Lymphoma, International Schools Association of Thailand, Prescription, Risk, China Biologic Products, Steroid, Pharmaceutical industry, Dietary supplement, Tacrolimus, Phase, Epidemiology

Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.

Key Points: 
  • Due to such factors, the atopic dermatitis treatment market is growing immensely during the forecast period.
  • Biological therapies such as anti-interleukin antibodies are widely used for treatment in the atopic dermatitis treatment market.
  • A recent wave of biological products prescribed for treating AD will likely create a lucrative opportunity for growth in the atopic dermatitis treatment market.
  • Despite the plethora of therapies currently available to patients with atopic dermatitis (AD), there is still room for improvement within the treatment space.

Dupilumab Emerging Drug Insight and Market Forecasts, 2032: Focus on 7MM - United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022
Health, Pharmaceutical, Food allergy, United Kingdom, Clinical trial, SWOT, Interleukin, Research, Chemokine, Dairy product, Cosmetics, Risk management, Pharmaceutical industry, Dupilumab

The "Dupilumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dupilumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • The report also highlights the Dupilumab research and development activity in Food Allergy details across the United States, Europe and Japan.
  • What are the forecasted sales of Dupilumab in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available in Food Allergy and how are they giving competition to Dupilumab for Food Allergy?

Severe Asthma Digital Marketing Trends Report 2022: Assess Key Digital Marketing Metrics Including Branded Websites for Patients and Healthcare Professionals, Mobile Apps, and Social Media Accounts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022
Digital Marketing, Managed Care, Communications, Health, Regeneron Pharmaceuticals, Digital, DDA, Social media, AstraZeneca, GSK, SEO, Teva, Asthma, HCP, Genentech, Reslizumab, HCPS, Novartis, Comparison, Patient, Pharmaceutical industry, Online shopping, Omalizumab, Dupilumab, Sanofi

For patient branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $4.2 million, followed by GSK's Nucala.com at approximately $900,000.

Key Points: 
  • For patient branded sites, Sanofi/Regeneron spent the most on DDA for Dupixent.com at approximately $4.2 million, followed by GSK's Nucala.com at approximately $900,000.
  • This report assesses key digital marketing metrics of pharma assets in severe asthma, including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts.
  • Understand the digital marketing competitive landscape in severe asthma, with a view of leading patient and HCP branded assets across different regions.
  • See what pharma social media accounts in severe asthma are the most active and achieving the most engagement.

Biogen Names Christopher Viehbacher President and Chief Executive Officer

Retrieved on: 
Thursday, November 10, 2022
Director, GLOBE, Regeneron Pharmaceuticals, Intellectual property, Health, Dupilumab, Leadership, BIIB, Partnership, Risk, Sale, Multiple sclerosis, Board, Drug discovery, Spinal muscular atrophy, Nobel Prize, Failure, NASDAQ, Share repurchase, Board of directors, U.S. Securities and Exchange Commission, Climate, Science, Neuroscience, Clinical trial, Pathology, Biotechnology, Public health, Patient, GlaxoSmithKline, Growth, Social media, Acquisition, Foundation, CNS, COVID-19, Chris Viehbacher, Management, Fine chemical, Pharmaceutical industry, Public relations, Biogen, Genzyme, Sanofi

CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ: BIIB) today announced that its Board of Directors has appointed Christopher A. Viehbacher as President and Chief Executive Officer and a member of the Board of Directors, effective November 14.
  • More recently, Viehbacher and Ernesto Bertarelli co-founded Gurnet Point Capital, a Cambridge-based healthcare investment fund, which has led to the creation and continuing development of many innovative companies.
  • He has also chaired or been a member of the board of a number of entrepreneurial companies in biotechnology.
  • Mr. Viehbacher said: It is both an honor and an exciting opportunity to join the Biogen team.

ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, October 28, 2022
Â, Clinical trial, ESDR, American depositary receipt, AD, Development, European Society for Medical Oncology, Feinberg School of Medicine, Itch, Safety, Nasdaq, B cell, CEO, European Academy of Microbiology, ADS, Patient, Research, Technology, EASI, News, GLOBE, Trial, Johns Hopkins University, SAN, Eosinophil, Investment, New York Public Library, ASLN, Congress, Sleep, Investor relations, Biomarker, Pharmaceutical industry, Cryptocurrency, Company, Dupilumab, Venereology, Dermatology

Cash used in operating activities for the third quarter of 2022 was US$9.1 million compared to US$7.6 million in the same period in 2021.

Key Points: 
  • Cash used in operating activities for the third quarter of 2022 was US$9.1 million compared to US$7.6 million in the same period in 2021.
  • Research and development expenses were US$8.0 million in the third quarter of 2022 compared to US$5.3 million in the third quarter of 2021.
  • General and administrative expenses were US$2.3 million in the third quarter of 2022 compared to US$2.8 million in the third quarter of 2021.
  • Net loss attributable to stockholders for the third quarter of 2022 was US$10.9 million compared to a net loss of US$8.6 million for the third quarter of 2021.

Early Launch Metrics Reveal an Impressive Start for Sanofi/Regeneron's Dupixent in Eosinophilic Esophagitis, According to Recent Research Conducted by Spherix Global Insights

Retrieved on: 
Friday, October 14, 2022
Adoption, Allergist, Physician, Eosinophilic esophagitis, Patient, Research, Sanofi, Degenerative disease, Budesonide, Gastroenterology, Benchmarking, Nephrology, Regeneron Pharmaceuticals, Pharmaceutical industry, Generic drug, Dupilumab, EOE

EXTON, Pa., Oct. 14, 2022 /PRNewswire/ -- In May of 2022, Sanofi/Regeneron's Dupixent (dupilumab) was granted approval by the U.S. FDA to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years and older, making the IL-4/13 inhibitor the first approved treatment for this debilitating disease. Spherix Global Insights' recent research via their Launch Dynamix™: Dupixent in EoE (US) service reveals swift uptake and unprecedented projected use of the brand at just three months post-approval. Indeed, nearly half of physicians (n=64 gastroenterologists and 10 allergists), sampled in September, report that they have already initiated trial of the drug in at least one EoE patient. 

Key Points: 
  • Spherix Global Insights' recent research via their Launch Dynamix: Dupixent in EoE (US) service reveals swift uptake and unprecedented projected use of the brand at just three months post-approval.
  • The vast majority of those reporting early experience also state that they are overall very satisfied with Dupixent.
  • Help, in any way, get the patient on the medication, whether it's financial, whether it's benefits verification, whatever it is."
  • Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence.

Press Release: Dupixent® (dupilumab) late-breaking Phase 3 data presented at UEG Week 2022 showed significant histological remission of eosinophilic esophagitis (EoE) in children 1 to 11 years old

Retrieved on: 
Tuesday, October 11, 2022
Dupilumab, Icahn School of Medicine at Mount Sinai, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Health, FDA, Population, UEG, EOE, Weight gain, Ageing, United European Gastroenterology, Pharmaceutical industry

Late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE) will be presented today at United European Gastroenterology (UEG) Week 2022.

Key Points: 
  • Late-breaking positive results from a Phase 3 trial evaluating the investigational use of Dupixent (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (EoE) will be presented today at United European Gastroenterology (UEG) Week 2022.
  • The data will be submitted to regulatory authorities around the world, starting with the U.S. Food and Drug Administration (FDA) in 2023.
  • Rates of treatment discontinuation due to AEs prior to week 16 were 0% (higher dose n=0/37, lower dose n=0/30) for Dupixent and 6% (n=2/34) for placebo.
  • In children, common symptoms of EoE include acid reflux, vomiting, abdominal discomfort, trouble swallowing, and a failure to thrive.